

The CCR5-delta32 variant might explain part of the association between COVID-19 and the chemokine-receptor gene cluster

Juan Gómez,^{1,8,12*} Elías Cuesta-Llavona,^{1,8*} Guillermo M. Albaiceta,^{2,8,9,10,11} Marta García-Clemente,³ Carlos López-Larrea,^{4,8,9,12} Laura Amado-Rodríguez,^{2,8,10,11} Inés López-Alonso,^{8,10} Tamara Hermida,³ Ana I. Enríquez,³ Helena Gil,^{1,8} Belén Alonso,^{1,8} Sara Iglesias,^{1,8} Beatriz Suarez-Alvarez,^{4,8,12} Victoria Alvarez,¹ Eliecer Coto

*These authors contributed equally to this work.

- 1 Genética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain.
- 2 Unidad de Cuidados Intensivos Cardiológicos, Hospital Universitario Central Asturias, Oviedo, Spain.
- 3 Neumología, Hospital Universitario Central Asturias, Oviedo, Spain.
- 4 Inmunología, Hospital Universitario Central Asturias, Oviedo, Spain.
- 5 Urgencias, Hospital Universitario Central Asturias, Oviedo, Spain.
- 8 Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain.
- 9 Universidad de Oviedo, Oviedo, Spain.
- 10 CIBER-Enfermedades Respiratorias. Instituto de Salud Carlos III. Madrid, Spain.
- 11 Instituto Universitario de Oncología del Principado de Asturias. Oviedo, Spain.
- 12 Red de Investigación Renal (REDINREN), Madrid, Spain.

Correspondence to:

Dr.EliecerCoto
Hospital Univ. Central Asturias
33011 – Oviedo – Spain
Tel. 34.985.10.55.00
Email: eliecer.coto@sespa.es

Abstract.

A polymorphism in the *LZTFL1* gene located in the chemokine-receptor gene cluster (chromosome 3p) has been associated with the risk of developing COVID-19. The chemokine receptor-5 (CCR5) maps to this region, and the common 32 bp deletion variant ($\Delta 32$) has been associated with the extent of inflammatory disease and the outcome in several viral diseases. Several studies have also suggested that the pharmacological targeting of CCR5 could reduce the impact of SARS-CoV-2 infection and the severity of COVID-19. We sought to investigate whether this polymorphism was associated with the risk of moderate-severe COVID-19.

We genotyped 294 patients who required hospitalization due to COVID-19 (85 were severe cases) and 460 controls. We found a significantly lower frequency of CCR5- $\Delta 32$ among the COVID-19 patients (0.10 vs 0.18 in controls; $p=0.002$, OR=0.48, 95%CI=0.29-0.76). The difference was mainly due to the reduced frequency of CCR5- $\Delta 32$ carriers in the severe, significantly lower than in the non-severe patients ($p=0.036$). Of note, we did not find deletion-homozygotes among the patients compared to 1% among controls. We also confirmed the association between a *LZTFL1* variant and COVID-19. Our study points to CCR5 as a promising target for treatment of COVID-19, but requires validation in additional large cohorts. In confirmed by others, the genetic analysis of CCR5-variants (such as $\Delta 32$) might help to identify patients with a higher susceptibility to severe COVID-19.

Key words: COVID-19; SARS-Cov-2; CCR5 delta32; genetic susceptibility

Introduction.

The clinical spectrum of COVID-19 varies from none or very mild-symptoms to moderate symptoms that required hospitalization, and in some cases severe pneumonia and acute respiratory distress syndrome (ARDS) that requires mechanical ventilation and admission into intensive care unit (ICU). An exacerbated immune response (*cytokine storm*) drives the severity of COVID-19 (**Bohn et al., 2020; Tang et al., 2020; Xiong et al., 2020**). Among other findings, COVID-19 patients showed elevated levels of IL-6 and other proinflammatory cytokines, chemokines, and chemokine-receptors (**Han et al., 2020; Wang et al., 2020; Zeng et al., 2020**).

The C-C chemokine-receptor-5 (CCR5) is expressed on several cell types, including T cells, macrophages and dendritic cells. CCR5 binds to the chemokine RANTES/CCL-5, that has been reported to be increased in COVID-19. CCR5 might thus play a role in inflammatory responses to coronaviruses infection. Human dendritic cells infected by SARS-CoV-1 showed increased CCR5 expression (**Law et al., 2009**). A single-cell RNA sequencing on nasopharyngeal and bronchial samples from patients with moderate or critical disease and healthy controls pointed to CCR5 pathways as suppressors of immune hyperactivation in critical COVID-19 (**Chua et al., 2020**). The levels of *ccr5* mRNA were increased in mice infected with the SARS-Cov (**Chen et al., 2010**). It has been reported that mice deficient in CCR5 infected with SARS-CoV-1 exhibited defects in directing inflammatory to the airway compared to wild-type mice (**Sheahan et al., 2008**). Mice lacking the CCR5 infected with a neurotropic coronavirus showed reduced macrophage infiltration and demyelination (**Glass et al., 2001**).

A recent study showed a beneficial effect of leronlimab (a CCR5 blocking antibody) on a reduced group of severe COVID-19 patients (**Patterson et al., 2020**). These patients showed a significant reduction of the SARS-Cov-2 viral load, with a rapid reduction of plasma IL-6 and restoration of the CD4/CD8 ratio. In another study a total of 23 hospitalized severe/critical COVID-19 patients received leronlimab subcutaneously (**Yang et al., 2020**). By day 30 after initial dosing Leronlimab was safe and well tolerated, 17/23 were recovered and 4/23 had died. The authors concluded that those with lower inflammatory markers had better outcomes, with IL-6 tending to fall overtime. Cenicriviroc (CVC) is a CCR5 antagonist with potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity. CVC showed anti SARS-Cov-2

activity by inhibition of virus-induced cell destruction and reduction of the viral RNA levels in culture supernatants of infected cells (**Okamoto et al., 2020**).

CCR5 is the receptor for HIV entry into the host cells, and a common variant that abrogates its expression in homozygotes (the 32 bp deletion, $\Delta 32$) is associated with the resistance to AIDS among HIV-exposed (**Kou and Kuang, 2019**). Approximately 1% of Europeans are $\Delta 32$ -homozygotes (**Figure 1**), and carriers of this variant would have a reduced inflammatory response. This effect on CCR5-mediated responses could explain the association of $\Delta 32$ with several immune-mediated diseases (**Hutter and Ganepola, 2011; González et al., 2001; Soto-Sánchez et al., 2010**). CCR5- $\Delta 32$ might also influence the immunological response to several viruses (**Ellwanger et al., 2020**). The first COVID-19 Genome Wide Association study (GWAs) reported a strong association with chromosome 3 variants in the chemokine-receptor cluster (**Ellinghaus et al., 2020**). CCR5 maps to this region and could thus partly explain the observed association with polymorphisms in the chemokine-receptor cluster. We sought to investigate whether CCR5- $\Delta 32$ was associated with the risk of developing COVID-19 or was a genetic modifier of disease severity.

Patients and Methods.

The study was based on 294 patients who required hospitalization due to COVID-19 (mean age 64.77 years, range 24-95) and 460 population age-matched controls (mean age 70.01 years, range 50-81). All the study participants were Caucasian from the region of Asturias (Northern Spain, total population 1 million). Severe cases (n=85) were defined as those in need of critical care support, including high-flow oxygen, positive-pressure ventilation (either invasive or non-invasive) or vasoactive drugs. The presence of comorbidities (hypertension, diabetes, hypercholesterolaemia) was obtained from the participants medical records. The study was approved by the Ethics Committee of Principado de Asturias (Oviedo, Spain), and all the patients or their representatives gave their consent to participate.

We genotyped two variants closely linked in the chromosome 3 chemokine receptor cluster, *LZTFL1* rs67959919 and *CCR5*- $\Delta 32$ (rs333). The genomic DNA was PCR-amplified with primers flanking the two polymorphic sites (**supplementary figure**). SNP rs67959919 was in complete linkage disequilibrium with rs11385942, associated with COVID-19 in a recent GWAs (**supplementary figure**) (**Ellinghaus et al., 2020**). For this SNP the PCRs were digested with the restriction enzyme *MspI* and the allele-

fragments visualised by agarose gel electrophoresis (**supplementary figure**). For the $\Delta 32$ the PCRs were directly electrophoresed on 4% agarose gels (**González et al., 2001; Soto-Sánchez et al., 2010**). The accuracy of the genotyping methods was validated by sequencing samples representative of the genotypes (**figure 2**). All the participant's data (age, sex, COVID-19 severity, hypertension, and genotypes) were collected in an excel file and in accordance to the requirements of the Ethical Committee. Statistical analysis was performed with the R-project free software (www.r-project.org). Logistic regression (linear generalized model, LGM) was used to compare mean values and frequencies between the groups.

Results and discussion.

The main finding of our study was a significantly lower frequency of CCR5- $\Delta 32$ among the COVID-19 patients (**table 1**). Multiple logistic regression with age, sex and hypertension showed that in our population carriers of the 32 bp deletion were significantly less frequent among the patients (30/294=0.10 vs 85/460=0.18 in controls; $p=0.002$, OR=0.48, 95%CI=0.29-0.76). The difference was mainly due to the reduced frequency of CCR5- $\Delta 32$ carriers in the severe-ICU group, significantly lower than in the non-severe patients ($p=0.036$). Of note, we did not find deletion-homozygotes among the patients compared to 1% among controls. Carriers of the deletion would express less membrane-bound receptor and an attenuated pro-inflammatory response mediated by the ligand binding to CCR5. This might explain the reported protective effect of $\Delta 32$ on the development of clinical manifestations with underlying inflammatory mechanisms, such as atherosclerosis and coronary heart disease (**Muntinghe et al., 2009; González et al., 2001; Vangelista and Vento, 2018**). In addition to the well-known protective effect against HIV-1, this variant has been investigated in reference to the clinical outcomes of several viral infections, such as hepatitis B and influenza A (**Ruiz-Mateos et al., 2018; Ellwanger et al., 2020**). Because CCR5 is not a recognised receptor for SARS-Cov-2 the most likely explanation for the protective effect of $\Delta 32$ in COVID-19 is an attenuated inflammatory response among the CCR5-deletion carriers. This finding was in agreement with a report that showed that mice lacking CCR5 infected with a neurotropic coronavirus showed an attenuated inflammatory response, with reduced macrophage infiltration and demyelination (**Glass et al., 2001**).

We confirmed the association between *LZTFL1* (SNP rs67959919) and the risk of

COVID-19. *LZTFLI* variants were associated with COVID-19 in a GWAs including participants from Italy and Spain. In our cohort the rare T-allele was associated with an increased risk of COVID-19 after correcting by age, sex and hypertension (**P=0.003, OR=1.86 (1.23-2.82)**), but we did not find significant difference between severe and non-severe cases (**Table 1**). We calculated the $\Delta 32$ - rs67959919 haplotype frequencies in patients and controls (**table 2**). The rs67959919 A – CCR5 non-deletion (wild-type) haplotype was significantly more common among the patients ($p < 0.001$, OR=2.01, 95%CI=1.45-2.79). We cannot exclude that the association between one of the variants was a consequence to its linkage-disequilibrium (LD) with the other, or with some not yet identified variant in the chemokine-receptor cluster. Multiple logistic regression with the two genotypes were independent predictors of COVID-19: *CCR5*- $\Delta 32$ carriers, $p=0.005$, OR=0.52 (95%CI=0.33-0.81); rs67959919-A carriers, $p=0.024$, OR=1.56 (95%CI=1.06-2.31).

The main limitation of our study was the reduced size of the patient's cohort. However, our results were in agreement with the reported association between chromosome 3p21.31 variants and COVID-19. In this way, the association between *CCR5*- $\Delta 32$ and COVID-19 seems plausible and deserves further validation in larger cohorts. If confirmed, the *CCR5* variants might serve as valuable markers to identify individuals predisposed to severe COVID-19. A limitation was also that we did not provide a functional link between the *CCR5* deletion and COVID-19 outcomes, and we cannot conclude whether this variant was associated with an overall resistance to SARS-Cov-2 infection or a reduced inflammatory response, or both. Although the *CCR5* has not a recognised role in SARS-CoV-2 binding to the host cell, a preliminary study showed that the *CCR5* inhibitor Maraviroc was able to decrease the extent of viral-cell fusion and the viral load (**Risner et al. 2020**). To determine whether *CCR5* has a direct role in SARS-CoV-2 infection studies with mice expressing the human viral receptor (ACE-2) and lacking *ccr5* should be of upmost relevance (**Winckler et al., 2020; Israelow et al., 2020**).

Finally, the pharmacological blockade of *CCR5* has been associated with an improvement of the symptoms in a group of severe COVID-19 patients. In a limited study involving 10 patients the anti-*CCR5* antibody Leronlimab showed an improvement of disease symptoms, with a rapid reduction of plasma IL-6 and restoration of the CD4/CD8 ratio and a significant reduction of the SARS-Cov-2 viral

load (**Patterson et al., 2020**). Also, in-vitro studies with SARS-Cov-2 infected cells showed that the CCR5 antagonist Cenicriviroc had potent anti-viral activity by inhibition of virus-induced cell destruction and reduction of the viral RNA levels (**Okamoto et al., 2020**). These and other studies pointed to CCR5 as a potential target for COVID-19 treatment. The genetic analysis of CCR5-variants, such as $\Delta 32$, might help to identify patients with a higher susceptibility to severe COVID-19.

Contributorship. All the authors contributed to this work by recruiting the patients and performing the genetic and statistical analysis. E.C. wrote the ms. and takes full responsibility for the accuracy of the data. All the authors approved the submission of this ms.

Data accessibility. To facilitate the revision of our results by other researchers, an excel file with the data is provided as supplementary file.

Competing interests. None of the authors have competing interests related to this work.

Acknowledgements. This work was supported by a grant from the Spanish Plan Nacional de I+D+I Ministerio de Economía y Competitividad and the European FEDER, grant ISCIII-Red de Investigación Renal-REDINREN RD16/9/5 (EC).

Table 1. Main values in the COVID19 patients and controls. Multiple logistic regression p-values, Odds ratios (OR) and 95% confidence intervals (CI) were calculated including age, sex, hypertension and the corresponding genotypes.

IQ=interquartile

	COVID N=294	CONTROLS N=460	SEVERE N=85	NON-SEVERE N=209
Male	176 (60%)	250 (54%)	64 (75%)	112 (55%)
Mean age, SD, years	63.18±14.75	70.48±6.94	65.74±11.16	62.14±15.89
Age IQ range, years	53-75	65-76	50-75	60-75
Hypertension	131 (45%)	154 (34%)	49 (58%)	82 (39%)
<i>CCR5</i> Δ32bp rs333				
Δ / Δ	0	4 (1%)	0	0
Δ / WT	30 (10%)	81 (18%)	4 (6%)	26 (14%)
WT / WT	264 (90%)	375 (81%)	81 (95%)	183 (88%)
Δ32 allele	0.05	0.06	0.05	0.10
p, OR (95%CI)*	P=0.002, OR=0.48 (0.29-0.76)		P=0.036, OR=0.30 (0.09-0.84)	
<i>LZTFL1</i> rs67959919				
AA	3 (1%)	4 (1%)	0	3 (1%)
AG	59 (20%)	60 (13%)	22 (26%)	37 (18%)
GG	232 (79%)	396 (86%)	63 (74%)	169 (81%)
A allele	0.13	0.10	0.11	0.07
p, OR (95%CI)**	P=0.003, OR=1.86 (1.23-2.82)		P=0.13, OR=1.62 (0.86-3.02)	

* Δ32 – carriers vs. WT/WT

** A-carriers vs GG

Table 2. Haplotype frequencies in controls, COVID19, and Europeans (EURX, obtained from <https://ldlink.nci.nih.gov/?tab=ldpair>).

The two markers were linked with $D' = 1.0$, $r^2 = 0.015$.

The rs67959919 A – CCR5-WT haplotype was significantly more common among the patients ($p < 0.001$, OR=2.01, 95%CI=1.45-2.79).

The rs67959919 G – CCR5-Δ32 haplotype was significantly less common in the patients ($p < 0.001$, OR=0.25, 95%CI=0.17-0.37).

rs67959919 – rs333	CONTROLS	COVID-19	EURX
A – Δ32	0	0	0
A - WT	114 (6%)	61 (11%)	16 (8%)
G - Δ32	177 (10%)	30 (6%)	21 (11%)
G -WT	1,554 (84%)	429 (83%)	161 (81%)

References.

- Bohn MK**, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. Pathophysiology of **COVID-19**: Mechanisms Underlying Disease Severity and Progression. *Physiology* (Bethesda). 2020; 35: 288-301.
- Chen J**, Lau YF, Lamirande EW, Paddock CD, Bartlett JH, Zaki SR, Subbarao K. Cellular immune responses to severe acute respiratory syndrome coronavirus (**SARS-CoV**) infection in senescent BALB/c mice: CD4+ T cells are important in control of **SARS-CoV** infection. *J Virol*. 2010 Feb;84(3):1289-301.
- Chua RL**, Lukassen S, Trump S, Hennig BP, Wendisch D, Pott F, et al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. *Nat Biotechnol*. 2020 Aug;38(8):970-979.
- Ellinghaus D**, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, et al. Genomewide **Association Study** of Severe **Covid-19** with Respiratory Failure. *N Engl J Med*. 2020 Jun 17: NEJMoa2020283.
- Ellwanger JH**, Kulmann-Leal B, Kaminski VL, Rodrigues AG, Bragatte MAS, Chies JAB. Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5 Δ 32 on viral diseases. *Virus Res*. 2020 Sep;286:198040.
- Glass WG**, Liu MT, Kuziel WA, Lane TE (2001) Reduced macrophage infiltration and demyelination in mice lacking the chemokine receptor CCR5 following infection with a neurotropic coronavirus. *Virology* 288: 8–17.
- González P**, Alvarez R, Batalla A, Reguero JR, Alvarez V, Astudillo A, Cubero GI, Cortina A, **Coto E**. Genetic variation at the chemokine receptors **CCR5/CCR2** in myocardial infarction. *Genes Immun*. 2001 Jun;2(4):191-5.
- Han H**, Ma Q, Li C, Liu R, Zhao L, Wang W, Zhang P, Liu X, Gao G, Liu F, Jiang Y, Cheng X, Zhu C, Xia Y. Profiling serum cytokines in **COVID-19** patients reveals IL-6 and IL-10 are disease severity predictors. *Emerg Microbes Infect*. 2020 Dec;9(1):1123-1130.
- Hütter G**, Ganepola S. The **CCR5-delta32** polymorphism as a model to study host adaptation against infectious **diseases** and to develop new treatment strategies. *Exp Biol Med* (Maywood). 2011 Aug;236(8):938-43.

Israelow B, Song E, Mao T, Lu P, Meir A, Liu F, Alfajaro MM, Wei J, Dong H, Homer RJ, Ring A, Wilen CB, Iwasaki A. Mouse model of **SARS-CoV-2** reveals inflammatory role of type I interferon signaling. *J Exp Med*. 2020; 217: e20201241.

Kou J, KuangYQ. Mutations in chemokine receptors and AIDS. *Prog Mol Biol Transl Sci*. 2019;161:113-124.

Law HK, Cheung CY, Sia SF, Chan YO, Peiris JS, Lau YL. Toll-like receptors, chemokine receptors and death receptor ligands responses in SARS coronavirus infected human monocyte derived dendritic cells. *BMC Immunol*. 2009 Jun 8;10: 35.

Muntinghe FL, Verduijn M, Zuurman MW, Grootendorst DC, Carrero JJ, Qureshi AR, et al. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. *J Am Soc Nephrol*. 2009 Jul;20(7):1641-9.

Okamoto M, Toyama M, Baba M. The chemokine receptor antagonist **cenicriviroc** inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res*. 2020 Jul 30;182:104902.

Patterson BK, Seethamraju H, Dhody K, Corley MJ, Kazempour K, Lalezari JP, Pang AP, Sugai C, Francisco EB, Pise A, Rodrigues H, Ryou M, Wu HL, Webb GM, Park BS, Kelly S, Pourhassan N, Lelic A, Kdouh L, Herrera M, Hall E, Aklin E, Ndhlovu L, Sacha JB. Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19. *medRxiv*. 2020 May 5:2020.05.02.20084673.

Risner KH, Tieu KV, Wang Y, Bakovic A, Alem F, Bhalla N, Nathan S, Conway DE, Macklin P, Narayanan A. **Maraviroc** inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture. *bioRxiv*. 2020; doi: 10.1101/2020.08.12.246389.

Ruiz-Mateos E, Tarancon-Diez L, Alvarez-Rios AI, Dominguez-Molina B, Genebat M, Pulido I, Abad MA, Muñoz-Fernandez MA, Leal M. Association of heterozygous CCR5 Δ 32 deletion with survival in HIV-infection: A cohort study. *Antiviral Res*. 2018 Feb;150:15-19.

Sheahan T, Morrison TE, Funkhouser W, et al. Myd88 is required for protection from lethal infection with mouse-adapted SARS-CoV. *PLoS Pathog*. 2008 Dec;4(12):e1000240.

Soto-Sánchez J, Santos-Juanes J, Coto-Segura P, Coto E, Díaz M, Rodríguez I, Alvarez V. Genetic variation at the **CCR5/CCR2** gene cluster and risk of psoriasis and psoriatic arthritis. *Cytokine*. 2010 May;50(2):114-6.

Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in **COVID-19**: The Current Evidence and Treatment Strategies. *Front Immunol.* 2020 Jul 10;11: 1708.

Vangelista L, Vento S. The Expanding Therapeutic Perspective of CCR5 Blockade. *Front Immunol.* 2018 Jan 12;8:1981.

Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. *J Leukoc Biol.* 2020 Jul;108(1):17-41.

Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, Fox JM, Chen RE, Earnest JT, Keeler SP, Ritter JH, Kang LI, Dort S, Robichaud A, Head R, Holtzman MJ, Diamond MS. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. *Nat Immunol.* 2020 Aug 24. doi: 10.1038/s41590-020-0778-2.

Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, Guo D, Hu W, Yang J, Tang Z, Wu H, Lin Y, Zhang M, Zhang Q, Shi M, Liu Y, Zhou Y, Lan K, Chen Y. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. *Emerg Microbes Infect.* 2020 Dec;9(1):761-770.

Yang B, Fulcher JA, Ahn J, Berro M, Goodman-Meza D, Dhody K, Sacha JB, Naeim A, Yang OO. Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab. *Clin Infect Dis.* 2020; ciaa1583. doi: 10.1093/cid/ciaa1583. PMID: 33079180

Zeng Z, Yu H, Chen H, Qi W, Chen L, Chen G, Yan W, Chen T, Ning Q, Han M, Wu D. Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China. *Crit Care.* 2020 Aug 27;24(1):525




Figure 1. Minor allele frequency of the *CCR5* and *LTZFL1* variants in different populations. Africans (AFR), Americans (AMR), East Asians (EAS), South Asians (SAS), Europeans (EUR), Iberians from Spain (IBS), and Asturians (AST, the study population from Spain). Data obtained from <https://www.ensembl.org>.




Figure 2. Sequence electropherograms (above) and gel electrophoresis of PCR fragments (below) corresponding at the three CCR5 32 bp deletion. The DNA was amplified with CTGTGTTTGGCTCTCTCCA and CCTTCTTCTCATTTCGACAC, and the PCRs electrophoresed on a 4% agarose gel to visualise the alleles as fragments of 222 bp (wild-type) and 190 bp ($\Delta 32$).